MBX MBX Biosciences, Inc.
MBX Biosciences, Inc. (MBX) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.76 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.6% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About MBX Biosciences, Inc.
MBX Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company's pipeline includes its lead product candidate MBX 2109, MBX 1416 and MBX 4291. MBX Biosciences Inc. is based in CARMEL, Ind.
Sector
Healthcare
Industry
Biotechnology